by Rod Raynovich | Mar 23, 2011 | Energy
Update after Inventory Report: Range $4.34-$4.48 Nat Gas prices up 10% in five sessions reached the highest level since Feb 4 as cold weather forecasts added to the bullish scenario. The EIA storage report showed a minor draw of 6 bcf which should continue with...
by Rod Raynovich | Mar 23, 2011 | 2023-24 Life Science Portfolios, BIOgraph
Good news boosted many biotech stocks today as the XOMA clinical trial failure of yet another diabetes drug did not scare away investors. Although the major ETF’s were barely up, there were a lot of individual stock winners. Within the Rayno Life Science...
by Rod Raynovich | Mar 23, 2011 | Weather//Ski Reports-Western US
Got Snow? LaNina Delivers If anyone figures out what to do with excess snow you can make a bundle. For sure the West Coast will have plenty of water from the winter snow pack which was already above normal 2 weeks ago. Trucking it somewhere for festivals do not make...
by Rod Raynovich | Mar 23, 2011 | BIOgraph
But Cardiovascular Biomarker Indicates Anti-Inflammatory Activity For XOMA052 Xoma (XOMA $3.55) said its lead Type 2 diabetes drug-XOMA052- in a Phase 2b study failed to meet its main goal of lowering blood glucose levels. The trial failed to achieve its primary...
by Rod Raynovich | Mar 18, 2011 | 2023-24 Life Science Portfolios, BIOgraph
Quest Diagnostics said today it would buy the diagnostics company Celera (CRA $8.10) for $671M.Celera business momentum had stalled in 2010 with Q4 Revenue down 11% at $34.9M with Net Income at 3 cents a share down from 4 cents a share in Q4 2009. Results from...
by Rod Raynovich | Mar 17, 2011 | Energy
Price Action More Bullish in a Bear Market Interest perked up again on nat gas chat and how it deserves more respect in US energy policy. The latest commentary postulates a shift from nukes to gas fired plants over the longer term due to increased costs caused by...
by Rod Raynovich | Mar 17, 2011 | 2023-24 Life Science Portfolios, BIOgraph
M&A Target?? Molecular diagnostic device maker was a mover today on low volume with an analyst initiation at outperform.The stock is near its recent 52 week high of $27.79. Cepheid is an emerging growth leader in molecular diagnostics with its GeneXpert platform...
by Rod Raynovich | Mar 15, 2011 | 2023-24 Life Science Portfolios, BIOgraph
Volatile Day on Wall Street-Biotech Stocks Are Holding Up Well with NASDAQ Down 1.18% Selected biotech stocks were in the green today responding to good news despite a nasty day in the market. The major ETF’s were down FBT ($38 down 1.09%), IBB ($94.25 down...
by Rod Raynovich | Mar 14, 2011 | BIOgraph, Reading List
University Start Ups: We Can Do It Just Show Me The Money To those of you who are familiar with Tech Transfer and university start-ups you know there are more opinions and technology than there is a money. See the article below that says universities are blowing...
by Rod Raynovich | Mar 14, 2011 | Energy
Japan Quake and Nuclear Concerns Shifts Attention to Nat Gas Japan will need more Liquid Natural Gas to replace nuclear energy needs driving up prices WW. However any changes in demand will grow slowly as LNG transport is obviously an issue. Many analysts and traders...